Is Foundayo® covered by Medicare? What to know about the GLP-1 Bridge program

Foundayo^® is one of the newest names in weight management, and it lands with a feature plenty of people have been waiting for: it’s a daily pill. It also arrives at an unusual moment for Medicare, which is about to cover certain weight-loss drugs for the first time in its history.

Medicare insures tens of millions of older adults and people with disabilities, and for nearly two decades, it hasn’t paid for any drug used only to lose weight. That exclusion goes back to how Part D was written when drug coverage began in 2006. Weight-loss medicines were treated as lifestyle products rather than medical ones. Now, weight loss medications are increasingly being seen as a necessary medication to treat the disease of obesity.

A temporary program called Medicare GLP-1 Bridge will launch on July 1, 2026, letting people who qualify fill Foundayo^® (orforglipron) and a short list of other weight-loss GLP-1s for $50 a month. 

Here’s how the Bridge handles Foundayo^®: who can use it, how it differs from regular Part D, what you’ll pay, and what to do if it doesn’t cover you. 

What is Medicare GLP-1 Bridge?

The Bridge is a short-term pilot program from the Centers for Medicare & Medicaid Services (CMS) that gives people with Medicare Part D, the medication coverage part, a lower price on GLP-1 weight-loss medications. Its purpose is to fill a gap while the government decides what permanent coverage for weight loss medication should look like. Standard Medicare still won’t broadly pay for weight-loss drugs; the Bridge is the temporary workaround.

It starts July 1, 2026, and is set to run through December 31, 2027. CMS first scheduled it to close at the end of 2026, then extended it by a year. The program runs on its own track rather than through your Part D plan, with a single central processor handling approvals, claims, and pharmacy payments, so your plan neither administers it nor pays for it.

The essentials:

• Four medications are covered: Foundayo^® (orforglipron), the Wegovy^® injection and pill, and the Zepbound^® KwikPen^® (no other forms of Zepbound®).
• You pay $50 a month, and that’s the same at any dose and for whichever of the four medications you and your provider choose.
• It’s nationwide, across all 50 states and U.S. territories.
• That $50 doesn’t count toward your Part D deductible or your $2,100 annual out-of-pocket cap (2026).

More about Foundayo^®: Covered under Medicare GLP-1 Bridge

Foundayo^® made the program’s short list of covered weight-management drugs.Foundayo^® with the active ingredient orforglipron, is a once daily GLP-1 pill. It’s made by Eli Lilly and was FDA-approved for weight loss in April 2026. 

GLP-1 is a hormone that reduces appetite, helps manage blood sugar, and slows how fast your stomach empties after you eat. When you take Foundayo®, it mimics these actions, helping you eat less and lose weight over time.

Foundayo^® is different from other GLP-1 medications because it is what’s called a small molecule instead of a peptide. This makes it a pill you can take any time of day, with or without food.

Under Bridge, Foundayo^® carries the standard $50 monthly copay for people who qualify. Access runs through your prescriber: once they confirm you meet the criteria and submit the paperwork, you fill the prescription and pay $50. 

One thing to hold onto: this coverage is separate from your traditional Part D benefit. It doesn’t change your existing drug plan, and your $50 doesn’t flow through the usual Part D cost phases.

Who qualifies for Foundayo^® through GLP-1 Bridge?

Two things have to line up. 

• First, your plan: you need to be enrolled in a Medicare Part D plan, either a standalone drug plan or a Medicare Advantage plan that includes drug coverage. 
• Second, your clinical picture.

A quick reminder on how Medicare’s parts handle drugs: Original Medicare (Parts A and B) doesn’t cover prescriptions at all. Drug coverage is under Part D and Medicare Advantage plans, which you pay extra for. 

To qualify for weight loss medications under Bridge, you need to meet certain BMI thresholds. 

Your BMI	What else has to be true
35 or higher	Nothing else needed; the BMI alone qualifies you.
30 or higher	Plus one of these: heart failure with preserved ejection fraction, blood pressure that stays above 140/90 despite two medications, or chronic kidney disease at stage 3a or beyond.
27 or higher	Plus one of these: pre-diabetes (by ADA guidelines), a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.

For people who are on a GLP-1 already, they would be assessed as of the day they started GLP-1 therapy, not where they stand today. The “when you started” detail is easy to miss, and it tends to help. Imagine someone who began a GLP-1 in mid-2025 at a BMI of 39 and has since worked it down to 33. Because the program looks back to when they started GLP-1 therapy, their prescriber can attest they met the BMI of 35 threshold then, and they stay eligible. The same holds if you started a GLP-1 before you ever enrolled in Medicare.

Documentation is the provider’s job. They submit a prior authorization that confirms your starting BMI and any qualifying condition, and that Foundayo^® is being prescribed for weight management alongside lifestyle changes. A few plan types are also left out: private fee-for-service plans, PACE programs, and certain others don’t qualify unless you also carry a standalone Part D plan.

What the GLP-1 Bridge program doesn’t cover

Bridge is only for medication used for weight management. Here’s what it doesn’t cover:

• If you need a GLP-1 for another condition that goes through your regular Part D plan, not Bridge. Foundayo isn’t currently approved for any other indications, but Wegovy® and Zepbund are, so review what they’re being prescribed for with your clinician.
• Extra Help (the low-income subsidy) doesn’t lower the $50 copay, even if it cuts your other prescription costs.
• The $50 never counts toward your Part D deductible or your $2,100 yearly out-of-pocket maximum.
• You can’t double up. If you already get a GLP-1 through Part D for an approved use, you generally stay on that coverage rather than moving the same drug to the Bridge.

CMS was clear that conditions like diabetes, obstructive sleep apnea (OSA), and MASH belong to Part D. People treated for those get their GLP-1 through their plan, not the Bridge, even if their BMI would otherwise qualify. Again, this applies to medications like Wegovy^® and Zepbound^®; Foundayo^® doesn’t yet have any non-weight-loss approval.

Does Medicare ever cover Foundayo^® outside the GLP-1 Bridge?

No, weight management is its only FDA-approved use right now.

Traditional Part D excludes drugs prescribed solely to lose weight, and that’s the only thing Foundayo^® is cleared to do. So there’s no “other diagnosis” that opens a standard Part D route the way heart disease or MASH can for Wegovy^®, or OSA can for Zepbound^®. For someone on Medicare who wants Foundayo^® for weight loss, the Bridge is the only covered path until it ends.

That could shift over time. Eli Lilly has said it intends to seek approval for Foundayo^® for type 2 diabetes. A diabetes indication would open the usual Part D coverage for that condition. Until any such approval lands, plan around the Bridge if weight loss is your goal, and budget for self-pay if you don’t qualify.

How does Foundayo^® compare with Wegovy® and Zepbound® under Bridge?

All four covered drugs cost the same $50 a month, so the choice comes down to which medication and form is right for you. Here’s how they line up on form and routine:

Medication	Form	How and when you take it	Bridge copay
Foundayo® (orforglipron)	Daily pill	Once a day, any time, with or without food. No water rules, no refrigeration.	$50/month
Wegovy® pill (semaglutide)	Daily pill	Once a day, in the morning on an empty stomach with a little plain water; wait about 30 minutes before eating or drinking.	$50/month
Wegovy® injection (semaglutide)	Weekly shot	One injection a week, on the same day each week.	$50/month
Zepbound® KwikPen (tirzepatide) Not covered: Single-dose pen and vial/syringe.	Weekly shot	One injection a week from a multi-dose pen; stored in the refrigerator.	$50/month

There’s no single “best” here; it’s about what fits your life. If you want a closer look at the two pills side by side, see our comparison of the Wegovy^® pill and Foundayo^®.

Does Medicare GLP-1 Bridge cover all GLP-1s?

No. Bridge names a specific set of weight-management products and leaves the rest to standard Medicare rules. The four covered drugs are Foundayo^®, the Wegovy^® injection, the Wegovy^® pill, and the Zepbound^® KwikPen. Several familiar GLP-1s aren’t included, though some may still be covered through Part D when they treat conditions like diabetes. Here’s the wider view:

Active ingredient	What it’s FDA-approved to treat	Where Medicare coverage stands*
Orforglipron	Foundayo® Weight management	Covered through the Bridge for weight loss if you qualify. No other FDA-approved use yet, so no standard Part D route.
Semaglutide	Wegovy® injection & pill: Weight management; heart-risk reduction; MASH Ozempic®/Ozempic pill® : Type-2 diabetes	Wegovy®: Both forms are covered through Bridge for weight loss. They go through Part D for heart disease or MASH. Ozempic®: May be covered by Part D for diabetes.
Tirzepatide	Zepbound® : Weight management; OSA Mounjaro®: Diabetes	Zepbound®: Only the KwikPen runs through the Bridge; the single-dose pen may be covered by Part D for OSA. The single-dose vials aren’t covered and are cash-pay only through Lilly Direct.  Mounjaro®: May be covered by Part D for diabetes.
Liraglutide	Saxenda®: Weight management Victoza® Type 2 diabetes; heart risk Generic liraglutide: Weight management; Type 2 diabetes; heart risk	Saxenda®: Not on the Bridge list, and not covered for weight loss. Victoza®: May be covered by Part D for diabetes or heart disease. Generic liraglutide: Not on the Bridge list, and not covered for weight loss. May be covered by Part D for diabetes or heart disease.

*Coverage depends on your specific Part D or Medicare Advantage plan’s formulary, prior authorization rules, and step therapy policies. Always confirm with your plan.

Read more: Does Medicare cover weight loss drugs?

Medicare Bridge: What changes on July 1, 2026?

That date is the switch flip. Until then, the old rules hold: no weight-loss coverage, and GLP-1s are covered by Medicare only when they treat a covered condition other than weight loss. From July 1 on, a few things are true:

• Eligible Part D members can fill Foundayo^®, the Wegovy^® injection or pill, or the Zepbound^® KwikPen for weight loss at $50 a month.
• Your $50 is far below the typical cost without insurance or through Eli Lilly’s cash-pay program. Manufacturers supply the program at a net price of $245 per monthly fill, which is what makes the low copay work.
• Your prescriber doesn’t need to be enrolled in Medicare to write the prescription or request Bridge approval.

Keep the big picture in mind: the underlying law hasn’t changed. Congress hasn’t opened Medicare to weight-loss drugs in general. This is a time-limited demonstration, and what happens after December 2027 is still unwritten, which is why it’s worth planning ahead rather than assuming the door stays open.

What if Medicare doesn’t cover Foundayo^® for you?

If you don’t qualify for Bridge, or you’re looking at the stretch before it opens, you still have a few moves.

Self-pay through the manufacturer. Eli Lilly sells Foundayo^® directly through LillyDirect, with cash-pay prices from $149 up to $299 depending on the dose. Our guide to Foundayo^® cost walks through the options.

A caution on savings cards. Lilly’s Foundayo^® Savings Card can drop the cost to as little as $25 a month, but it’s for people with commercial insurance only. Medicare, Medicaid, and other government coverage are excluded, so it isn’t an option if you’re on Medicare. As of its launch, Foundayo^® also wasn’t part of Lilly’s patient assistance program for lower-income people.

Other coverage and other support. If you have diabetes alongside weight concerns, your provider might prescribe a different GLP-1 that Part D already covers for that condition. And medication isn’t the only route to results. 

Frequently asked questions about Medicare Bridge coverage for Foundayo^®

If you have Medicare and are interested in Foundayo^®, your first step is understanding whether your specific plan includes coverage for the medication. Coverage can vary depending on your Medicare plan type, the reason the medication is prescribed, and current Medicare policies. Even if coverage is available, costs and eligibility requirements may differ from one plan to another. Here’s what to know about getting Foundayo^® through Medicare.

How do I get Foundayo^® if I have Medicare?

Once Bridge starts on July 1, 2026, it runs through your prescriber. If you’re in an eligible Part D plan and meet the criteria, they submit a prior authorization to the Bridge’s central processor, documenting your starting BMI and any qualifying condition. After it’s approved, you fill your Foundayo^® prescription and pay the $50 copay. You don’t need to sign up for Bridge yourself.

How much does Foundayo^® cost under Medicare?

Through the Bridge, $50 a month, the same at any dose. Remember that the $50 doesn’t count toward your deductible or out-of-pocket maximum, since the program sits outside regular Part D.

What diagnosis will cover Foundayo^®?

For the Bridge, it’s weight management paired with a qualifying BMI: 35 or higher on its own, or a lower BMI (30+ or 27+) combined with a specific condition like a heart, kidney, or blood pressure issue, pre-diabetes, or a history of heart attack or stroke. What counts is your status when you started GLP-1 therapy, so weight you’ve already lost won’t disqualify you.

Does standard Medicare Part D cover Foundayo^®?

No. Federal Part D rules exclude drugs prescribed solely to lose weight, and weight management is currently Foundayo^®’s only approved use. That leaves no standard Part D pathway for it today. If Eli Lilly later gets approval for another condition, such as type 2 diabetes, that could change. Until then, Bridge is the Medicare route.

The bottom line: Medicare will cover Foundayo^® through Medicare Bridge for some people

Here’s the short version. Medicare hasn’t started covering weight-loss drugs as a standard benefit. What it has done is open a temporary side door, the Medicare GLP-1 Bridge, that puts Foundayo^® within reach at $50 a month, starting July 1, 2026, and running through December 2027.

Because weight management is Foundayo^®’s only approved use right now, the Bridge is effectively the one way Medicare covers it, which makes timing matter. If a daily pill appeals to you, ask your provider whether your starting BMI and health history make a weight loss medication right for you. You’ll also have the Wegovy^® pill, the Wegovy^® injection, and the Zepbound^® KwikPen as covered options at the same price.

This article is for general education and isn’t medical or insurance advice. Medicare rules, drug approvals, and prices change often. Confirm the current details with CMS, Medicare.gov, your plan, and your healthcare provider before deciding anything.